Contineum Therapeutics, Inc. Class A Common Stock
CTNM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $11 | $14 | $14 | $13 |
| G&A Expenses | $0 | $4 | $4 | $4 |
| SG&A Expenses | $4 | $4 | $4 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$102 |
| Operating Expenses | $15 | $18 | $18 | -$85 |
| Operating Income | -$15 | -$18 | -$18 | $85 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $2 | $2 | -$99 |
| Pre-Tax Income | -$13 | -$16 | -$16 | -$15 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$13 | -$16 | -$16 | -$15 |
| % Margin | – | – | – | – |
| EPS | -0.45 | -0.62 | -0.62 | -0.65 |
| % Growth | 27.4% | 0% | 4.6% | – |
| EPS Diluted | -0.45 | -0.62 | -0.62 | -0.65 |
| Weighted Avg Shares Out | 28 | 26 | 26 | 26 |
| Weighted Avg Shares Out Dil | 28 | 26 | 26 | 26 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $2 | $3 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$13 | -$16 | -$18 | -$14 |
| % Margin | – | – | – | – |